Compared with plasma EVs derived from healthy controls, VEGF and CD133 constitute a unique CRC signature in plasma EVs of CRC patients, which can be used for the companion diagnosis of CRC patients treated with bevacizumab196. The gene discussed is PROM1; the disease is colorectal carcinoma.